Related references
Note: Only part of the references are listed.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update
Yun-Fan Liaw et al.
HEPATOLOGY INTERNATIONAL (2012)
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
George Papatheodoridis et al.
JOURNAL OF HEPATOLOGY (2012)
Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis
H. L. Y. Chan et al.
JOURNAL OF VIRAL HEPATITIS (2012)
Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B
E. Jenny Heathcote et al.
GASTROENTEROLOGY (2011)
Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B
Stefan Mauss et al.
JOURNAL OF HEPATOLOGY (2011)
Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B
Edward J. Gane et al.
LIVER INTERNATIONAL (2011)
Hepatitis B e Antigen Seroconversion: A Critical Event in Chronic Hepatitis B Virus Infection
Yun-Fan Liaw et al.
DIGESTIVE DISEASES AND SCIENCES (2010)
Entecavir Treatment for up to 5 Years in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B
Ting-Tsung Chang et al.
HEPATOLOGY (2010)
Kinetics of Hepatitis B Surface Antigen Decline During 3 Years of Telbivudine Treatment in Hepatitis B e Antigen-Positive Patients
Karsten Wursthorn et al.
HEPATOLOGY (2010)
HBSAG KINETICS OF DECAY AND BASELINE CHARACTERISTICS OF HBEAG-POSITIVE PATIENTS WITH CHRONIC HEPATITIS B FOLLOWING 3 YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT
E. Gane et al.
JOURNAL OF HEPATOLOGY (2010)
Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B
R. G. Gish et al.
JOURNAL OF VIRAL HEPATITIS (2010)
2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B
Yun-Fan Liaw et al.
GASTROENTEROLOGY (2009)
Long-Term Monitoring Shows Hepatitis B Virus Resistance to Entecavir in Nucleoside-Naive Patients Is Rare Through 5 Years of Therapy
Daniel J. Tenney et al.
HEPATOLOGY (2009)
Chronic Hepatitis B: Update 2009
Anna S. F. Lok et al.
HEPATOLOGY (2009)
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B
Stefan Zeuzem et al.
JOURNAL OF HEPATOLOGY (2009)
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: Recommendations for a standardized approach
Jean-Michel Pawlotsky et al.
GASTROENTEROLOGY (2008)
The Roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B
Edward J. Gane
HEPATOLOGY INTERNATIONAL (2008)
Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial
Jinlin Hou et al.
HEPATOLOGY (2008)
Telbivudine versus lamivudine in patients with chronic hepatitis B
Ching-Lung Lai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B
Emmet B. Keeffe et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years
Stephanos J. Hadziyannis et al.
GASTROENTEROLOGY (2006)
Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy
MF Yuen et al.
HEPATOLOGY (2001)
Share Paper
